Cancer is smart.
Together, we can
be smarter.
Accelerating the fight against cancer requires the entire industry to work together. Our products connect community oncologists, academics, hospitals, life science researchers and regulators on a shared technology platform.
Together, we can learn from the experience of every patient.
For Community Oncology
OncoCloud is the most comprehensive suite of software and services in community oncology. Using our technology, community clinics are providing better care for patients while remaining efficient, independent and financially successful.
Learn more
For Life Sciences
With access to billions of data points on millions of cancer patients treated across our network, Flatiron is changing the way life science companies are using real-world data to accelerate research and generate evidence.
Learn more
For Academics & Hospitals
Flatiron’s enriched data infrastructure helps hospitals and academic centers unlock the promise of their EHR data. Researchers and clinicians now have access to research-grade insights from within and beyond the walls of their institution.
Learn moreDo well by doing good. Join the leading tech company in the fight against cancer.
Life at Flatiron
The talent and dedication of the people working at Flatiron makes everything we do possible. If you’re passionate about having an impact on accelerating cancer research and improving patient care, we’d love to hear from you.
Open positionsLet us tell you more.
We will email you to start the conversation.
The Deeply Human Core Of Roche's $2.1 Billion Tech Acquisition -- And Why It Made It
Flatiron has entered into an agreement to be acquired by Roche, providing us with an accelerated ability to achieve our mission: improving lives by learning from the experience of every cancer patient.
Why We Love Running Hackathons at Flatiron
Engineers Sam Bail & Ovadia Harary on the importance of hackathons to Flatiron's culture, including everything from encouraging cross-functional collaboration, allowing people to stretch themselves professionally, helping with soft skills development and much more.
Characteristics of Real‐World Metastatic NSCLC Patients Treated with Nivolumab & Pembrolizumab Post-Approval
The FDA and Flatiron Health analyzed real‐world usage patterns of PD‐1 inhibitors to inform future studies of subpopulations underrepresented in clinical trials.